07/17/2025
6:54 PM | BlackRock, Inc. (Filed by)
Inozyme Pharma (Subject)
| Form SCHEDULE 13G/A | |
07/11/2025
5:02 AM | Inozyme Pharma (Filer)
| Form 15-12G | |
07/03/2025
6:16 PM | Inozyme Pharma (Issuer)
Subramanian Sanjay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2025
5:59 PM | Hopfner Robert Lorne (Reporting)
Inozyme Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2025
6:03 PM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2025
6:04 PM | Inozyme Pharma (Issuer)
Sullivan Lynne Marie (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2025
6:07 PM | Bolte Axel (Reporting)
Inozyme Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2025
6:08 PM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/01/2025
11:15 PM | Inozyme Pharma (Filer)
| Form EFFECT | |
07/01/2025
11:15 PM | Inozyme Pharma (Filer)
| Form EFFECT | |
07/01/2025
8:29 AM | Inozyme Pharma (Filer)
| Form POS AM | |
Get the Latest News and Ratings for INZY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. |
07/01/2025
8:43 AM | Inozyme Pharma (Filer)
| Form S-8 POS | |
07/01/2025
8:44 AM | Inozyme Pharma (Filer)
| Form S-8 POS | |
07/01/2025
8:45 AM | Inozyme Pharma (Filer)
| Form S-8 POS | |
07/01/2025
8:48 AM | Inozyme Pharma (Filer)
| Form S-8 POS | |
07/01/2025
8:49 AM | Inozyme Pharma (Filer)
| Form S-8 POS | |
07/01/2025
8:51 AM | Inozyme Pharma (Filer)
| Form S-8 POS | |
07/01/2025
8:54 AM | Inozyme Pharma (Subject)
Nasdaq Stock Market LLC (Filed by)
| Form 25-NSE | |
07/01/2025
8:18 AM | BIOMARIN PHARMACEUTICAL INC (Filed by)
Inozyme Pharma (Subject)
| Form SC TO-T/A | |
07/01/2025
8:21 AM | Inozyme Pharma (Subject)
| Form SC 14D9/A | |
07/01/2025
8:25 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/01/2025
8:27 AM | Inozyme Pharma (Filer)
| Form POS AM | |
06/20/2025
6:29 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/20/2025
6:31 PM | Inozyme Pharma (Filer)
| Form DEFA14A | |
06/17/2025
6:28 AM | BIOMARIN PHARMACEUTICAL INC (Filed by)
Inozyme Pharma (Subject)
| Form SC TO-T/A | |
06/17/2025
5:15 AM | Inozyme Pharma (Subject)
| Form SC 14D9/A | |
06/04/2025
4:09 PM | GLAZER CAPITAL, LLC (Filed by)
Inozyme Pharma (Subject)
| Form SCHEDULE 13G | |
06/04/2025
3:51 PM | Inozyme Pharma (Subject)
| Form SC 14D9/A | |
06/04/2025
3:32 PM | BIOMARIN PHARMACEUTICAL INC (Filed by)
Inozyme Pharma (Subject)
| Form SC TO-T/A | |
06/02/2025
6:35 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/02/2025
6:14 AM | Inozyme Pharma (Subject)
| Form SC 14D9 | |
06/02/2025
5:25 AM | BIOMARIN PHARMACEUTICAL INC (Filed by)
Inozyme Pharma (Subject)
| Form SC TO-T | |
05/30/2025
4:24 PM | Affinity Asset Advisors, LLC (Filed by)
Inozyme Pharma (Subject)
| Form SCHEDULE 13G/A | |
05/19/2025
8:23 PM | Inozyme Pharma (Subject)
| Form SC14D9C | |
05/19/2025
4:22 PM | BIOMARIN PHARMACEUTICAL INC (Filed by)
Inozyme Pharma (Subject)
| Form SC TO-C | |
05/16/2025
8:44 PM | BIOMARIN PHARMACEUTICAL INC (Filed by)
Inozyme Pharma (Subject)
| Form SC TO-C | |
05/16/2025
4:16 PM | BIOMARIN PHARMACEUTICAL INC (Filed by)
Inozyme Pharma (Subject)
| Form SC TO-C | |
05/16/2025
3:40 PM | Inozyme Pharma (Subject)
| Form SC14D9C | |
05/16/2025
7:06 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/14/2025
6:33 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/14/2025
6:36 AM | Inozyme Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
The End of Elon Musk…? (Ad) The End of Elon Musk? Don't make him laugh.
Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again.
And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again.
According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. Click here to see why the "End of Elon" crowd is about to be wrong again. |
04/23/2025
9:28 AM | EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Inozyme Pharma (Subject)
| Form SCHEDULE 13G/A | |
04/03/2025
3:27 PM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/02/2025
3:27 PM | Inozyme Pharma (Issuer)
Subramanian Sanjay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/02/2025
3:29 PM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/17/2025
3:24 PM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/17/2025
3:25 PM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/17/2025
3:26 PM | Inozyme Pharma (Issuer)
Subramanian Sanjay (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/10/2025
4:17 PM | Inozyme Pharma (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/10/2025
7:31 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/10/2025
7:31 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/10/2025
7:32 AM | Inozyme Pharma (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/10/2025
7:32 AM | Inozyme Pharma (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/14/2025
12:59 PM | Inozyme Pharma (Subject)
SAMLYN CAPITAL, LLC (Filed by)
| Form SCHEDULE 13G/A | |
01/10/2025
7:06 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
11:19 AM | EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Inozyme Pharma (Subject)
| Form SC 13G/A | |
11/05/2024
7:33 AM | Inozyme Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/05/2024
7:31 AM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/24/2024
3:34 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/24/2024
1:02 PM | BlackRock, Inc. (Filed by)
Inozyme Pharma (Subject)
| Form SC 13G | |
10/03/2024
7:58 PM | Inozyme Pharma (Issuer)
Treco Douglas A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/03/2024
7:57 PM | Inozyme Pharma (Issuer)
Winton Matthew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/06/2024
3:52 PM | Inozyme Pharma (Filer)
| Form 424B5 | |
08/06/2024
3:54 PM | Inozyme Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
